This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1203 entries already.
UK-based biotech startup Fluidic Analytics has raised 27m for its proteomics platform. The financing round was led by Draper Esprit, with participation from Delin Ventures, BGF, IQ Capital, and Amadeus […]
French Carbios SA has signed a letter of intent with PVC giant Kem One to implement a demonstration plant to provide proof of concept of Carbios groundbreaking enzymatic PET depolymerisation […]
German Adrenomed AG has bagged 24m in equity financing from HBM Healthcare Investments and Wellington Partners.
Researchers at Genentech have locally blocked lung inflammation in a mouse model for asthma by administration of an inhalable JAK1 inhibitor.
The European Investment Bank (EIB) has lent antiinfectives company F2G Biotech Ltd 24m for antifungal research and innovation under the InnovFin Infectious Diseases Finance Facility (IDFF).
Researchers at Cancer UK have slowed down tumour growth by simply feeding mice that carry human tumour xenografts with mannose instead of glucose.
Researchers at IRB Barcelona report that tumours may become more aggressive following treatment with drugs that inhibit epigenetic factors.
Researchers at IRB Barcelona report that tumours may become more aggressive following treatment with drugs that inhibit epigenetic factors.
Inflammosome inhibitor specialist Inflazome Ltd has raised 40m in a Series B financing led by Forbion with co-investors Longitude Capital, Novartis Venture Fund and Fountain Healthcare Partners.
Boehringer Ingelheim and Epizyme, Inc. will collaborate in the field of small molecule cancer drugs that target unaddressed epigenetic targets within the helicase and histone acetyltransferase families.